Parkwalk closes Arvia investment
We are pleased to announce that Parkwalk have made a follow-on investment into Arvia Technology from the Parkwalk Technology EIS Funds. This round has been led by a new Investor and secures the company’s current funding requirements for around 30 months. This is the third investment round in which Parkwalk has participated.
Arvia is exploiting a disruptive new technology for the treatment of organic and microbial wastes in water. Invented and spun-out in 2007 from the University of Manchester, Arvia has received a plethora of major sustainability and technology innovation awards over the last five years. The company has 21 full-time employees at its laboratories in Daresbury.
Arvia is now gaining the attention of a number of the global water technology players and momentum with customer site trials in the nuclear sector. The unique part of Arvia’s technology is it combines two traditional treatment methods for water, adsorption and electrochemical treatment while using a highly conductive media, which can be regenerated within the process. Turning the adsorbed pollutants into trivial quantities of vented gases, whereas where as traditional treatment methods, require the media to be replaced, or the amount of energy required makes the process cost prohibitive. This gives rise to the following generic benefits of Arvia’s technology that apply across all application areas:
- Complete on-site treatment, in a robust low maintenance system
- No or minimal added process chemicals
- Upon decommissioning leaves a secondary solid waste which has an authorised well established disposal route
- Low energy, especially for low levels of difficult to treat organics
At the heart of Arvia’s technology is the patented adsorbent media Nyex, based on dense graphite, which has a high electrical conductivity.
